Revised_Figure 12 A-G showed that the IC50 scores of Rucaparib, CCT018159, PF-4,708,671, Fedratinib, Pazopanib, Lapatinib, and XMD8-85 were lower in the SPTBN1 high-expression UVM group compared with those in low-expression group (all p < 0.001), reflecting that UVM patients with high expression of SPTBN1 may exhibit a favorable response to anti-cancer targeted therapy. This evidence concerns the gene SPTBN1 and cancer.